This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BioLineRx Ltd. (NASDAQ:
BLRX.TA), a biopharmaceutical development company, announced the release today of its investor relations app for iPhone, now available for free at the Apple App store on the iPhone or at
The BioLineRx investor relations app for iPhone, designed, created and powered by theIRapp (
www.theirapp.com), allows users to navigate the Company’s investor relations materials as well as receive a stock quote and other important stock information. Features in the app include the latest press releases and SEC filings as well as background information, archived audiocasts and presentations from the Company.
“We are very excited to have launched the IR app, which we feel will resonate well with our global investor base and offer them real-time access to the most pertinent information on our Company’s stock,” commented Philip Serlin, Chief Financial and Operating Officer of BioLineRx. “With investors spanning the globe, and listings on NASDAQ and the Tel Aviv Stock Exchange, BioLineRx recognizes the importance of enabling our shareholders to have instant access to our corporate and stock information. The BioLineRx IR app will prove to be an essential tool to both existing and future shareholders as they monitor our Company’s progress.”
To be added to the BioLineRx investor email list, please email
firstname.lastname@example.org with BLRX in the subject line.
BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development and BL-7040 for treating Inflammatory Bowel Disease (IBD) is commencing a Phase II trial. In addition, BioLineRx has eleven products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.